Luca AICell

What Luca AICell does

Luca AICell (루카에이아이셀) is a South Korean lipid biotechnology platform company founded in December 2020 and headquartered in Anyang-si, Gyeonggi-do. The company is a subsidiary/related entity of publicly listed THE E&M (KOSDAQ: 089230). Its core technology is a proprietary Lipid Nano Particle (LNP) manufacturing platform called LUCA Cycle, based on artificial cell membrane (lipid bilayer) science, which enables uniform LNP production in an 18nm-400nm size range while operating outside over 700 existing mRNA vaccine patents. Adjacent technologies include LUCA Lipid Bilayer (LLB) antifouling coatings, Bicelle/SALB/BCLB surface coatings, and the LEAD (Lipid Envelope Antiviral Disruption) antiviral peptide platform that has completed preclinical work on 13 viruses.

The company monetizes across four revenue streams: (1) direct sales of finished medical products such as the LUCA V-Defense nasal spray, COVID-19 rapid antigen diagnostic kits (with LLB coating), and LUCA One-Step/5-Min Blocker research reagents via Naver Smart Store and Amazon e-commerce; (2) LNP manufacturing equipment sales through the three-tier LUCA Cycler product line (LAB Manual, LAB Automation, Equipment) to research institutions and pharma manufacturers; (3) technology licensing and drug delivery system (DDS) partnerships with pharmaceutical companies for new drug co-development; and (4) contract research services, including work funded by the NIH NIAID AViDD program through Stanford University. Primary customer segments are pharmaceutical companies, with secondary segments in research institutions, healthcare providers/consumers, and cosmetics/health functional foods.

The company's go-to-market combines B2B enterprise licensing and partnership sales for the pharma vertical with direct-to-consumer e-commerce for medical devices and research reagents. Strategic partnerships include NIH/NIAID (where co-founder Professor Nam-Joon Cho is the only non-US scientist in the AViDD program), Stanford University, NTU Singapore (hosting the LUCA Research Institute), KDB Industrial Bank (lead investor, ~50B KRW in 2022), ABITEC, the UN-affiliated International Vaccine Institute, and a network of academic collaborators across Korea, the US, Europe, Mongolia, and Brazil. The company has secured ISO 13485, CE Mark, GMP (IVD and medical device), and ISO 27001 certifications, supporting international commercialization, and has stated a goal of listing on Kosdaq.

Name

Luca AICell

Legal name

주식회사 루카에이아이셀

Website

https://lucaaicell.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Drug Delivery Systems

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)

SIC

Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

mRNA/LNP & Nucleic Acid Therapeutics CDMO (HLAGABAF)

Keywords

• Lipid nanoparticle technology
• Drug delivery systems
• Antiviral therapeutics
• Medical device manufacturing
• Diagnostic test kits

Headquarters

HQ city

Seongnam

HQ country

South Korea

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Medical Device Sales: Direct sales of finished medical products including LUCA V-Defense nasal spray, COVID-19 rapid diagnostic kits, and blocking solutions for research (ELISA, Western blot). Products sold through e-commerce platforms and potentially retail channels.
2. Technology Licensing and DDS Partnerships: Licensing of LNP drug delivery technology to pharmaceutical partners for new drug development. Partnership arrangements where LUCA provides DDS solutions for partner APIs in exchange for licensing fees or revenue sharing.
3. LNP Manufacturing Equipment Sales: Sale of LUCA Cycler equipment for LNP production to research institutions, pharmaceutical companies, and biotech firms. Equipment ranges from laboratory manual systems to automated production-scale equipment.
4. Contract Research Services: R&D collaboration with pharmaceutical companies and research institutions. NIH AViDD program funding for antiviral drug development research conducted in partnership with Stanford University.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

Luca AICell is a lipid biotechnology platform company that develops and manufactures lipid nanoparticle (LNP)-based products including broad-spectrum antiviral peptide drug candidates (LEAD technology), LNP drug delivery systems licensed to pharmaceutical partners, the LUCA Cycler™ LNP manufacturing equipment line, the LUCA V-Defense nasal spray medical device, LLB-coated COVID-19 rapid antigen diagnostic kits, and BCLB-based blocking reagents for ELISA and Western blot research applications.

Product overview

Luca AICell is a Lipid biotechnology platform company developing products across four main areas: (1) novel drug development using Antiviral Peptide technology targeting lipid-enveloped viruses, (2) LNP-based drug delivery systems (DDS) for pharmaceutical partners, (3) LNP manufacturing equipment (LUCA Cycler™) for research and production scales, and (4) consumer/industrial applications including medical devices (LUCA V-Defense Nasal Spray), in vitro diagnostics (LUCA COVID-19 Ag Test Kits with LLB coating), and research reagents (LUCA Blocker Solutions for ELISA/Western Blot). The company leverages its proprietary LUCA Lipid Bilayer (LLB) and BiCelle-mediated supported Lipid Bilayer (BCLB) technologies across its product portfolio.

Differentiator

Problem solved

Functional benefit

Brands

• LUCA V-Defense: Nasal spray product coated with lipids to block external contaminants and prevent respiratory virus infection and allergies.
• LUCA COVID-19 Ag Nasal Home Test
• LUCA One-Stop Blocker / 5-Min Blocker
• LUCA Cycler
• LLB (LUCA Lipid Bilayer)
• SALB (Solvent-Assisted Lipid Bilayer)
• BCLB (BiCelle-mediated supported Lipid Bilayer)
• LEAD (Lipid Envelope Antiviral Disruption)

Products and services

• LUCA V-Defense Nasal Spray (루카 브이디펜스 비강스프레이)

Quantifiable outcome

• 10% improvement in diagnostic kit accuracy due to LLB coating
• +4 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Seven partnerships are on record, tiered core, flagship and minor.

• Stanford UniversitycoreStrategic or Co-development Partner · 1 July 2022Joint preclinical research on broad-spectrum antiviral therapeutics with Stanford Medical School research team. Part of NIH AViDD center at Stanford. Professor Cho serves as co-lead on 2 of 7 projects within the Stanford AViDD center.
• NTU Singapore (Nanyang Technological University)coreStrategic or Co-development Partner · 1 September 2021Research Collaboration Agreement signed for fundamental lipid nano-assembly technology research including LNPs, antiviral peptides, and prototype development. Location of LUCA Research Institute at NTU for advanced research.
• ABITEC (US lipid company)flagshipStrategic or Co-development Partner · 1 September 2021Memorandum of Understanding signed with ABITEC, a US-based lipid company, to establish standard portfolio for drug delivery systems. Strategic partnership for lipid-based pharmaceutical applications.
• ONOM Foundation Mongolia ( Mongol O.NOM Foundation's Hepatitis Center)minorStrategic or Co-development Partner · 1 March 2021Memorandum of Understanding signed for hepatitis diagnosis accuracy verification with Mongolia's ONOM Foundation Hepatitis Center.
• IVI (International Vaccine Institute, UN)coreStrategic or Co-development Partner · 1 January 2021Vaccine co-development contract signed with UN-affiliated International Vaccine Institute for joint vaccine development using LNP technology.
• Global Research NetworkminorStrategic or Co-development Partner · 1 January 2021Collaborative research relationships with Stanford, Harvard, UCLA (US), Utrecht, Twente (Netherlands), Ghent (Belgium), ONOM (Mongolia), UFMG (Brazil). Global cooperation for joint research and clinical trials.
• Domestic Korean Research PartnersminorStrategic or Co-development Partner · 1 January 2021Joint research agreements with SNU Hospital (Seoul National University Hospital), CHA Biotech, UNIST, and Hongik University for LNP and lipid technology applications.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Emerging players

• Translate Bio (Sanofi): Translate Bio (acquired by Sanofi in 2021) developed mRNA therapeutics using LNP delivery for cystic fibrosis and other indications. It represents the 'acquired early-stage LNP platform' exit archetype relevant to Luca.
• Arcturus Therapeutics: Arcturus is a clinical-stage mRNA medicines company using LNP delivery for vaccines and rare disease therapeutics, intersecting directly with Luca AICell's LNP-based drug development ambitions.

Direct peers

• Precision NanoSystems (Cytiva): Precision NanoSystems (now part of Cytiva/Danaher) manufactures the NanoAssemblr LNP production platform, the most direct competitive offering to Luca AICell's LUCA Cycler equipment line.
• Acuitas Therapeutics: Acuitas develops the lipid nanoparticle (LNP) delivery technology used in Pfizer–BioNTech's Comirnaty vaccine. It is the closest pure-play LNP technology peer to Luca AICell, competing in the same nucleic-acid drug delivery space.
• Genevant Sciences: Genevant is a lipid nanoparticle delivery technology company focused on nucleic acid therapeutics (RNA, gene editing). Its platform approach to LNP-enabled drug development is directly comparable to Luca AICell's LNP platform.

Others

• Evonik Industries: Evonik supplies specialty lipids and pharmaceutical excipients used in LNP formulations, including mRNA vaccine production. As a raw-materials/CMO partner it sits adjacent to Luca rather than in direct competition.
• CordenPharma: CordenPharma is a CDMO supplying lipid excipients and LNP formulation services to mRNA developers. It is comparable as a lipid-focused supplier/CDMO in the same LNP value chain.

Broad incumbents

• BioNTech: BioNTech is the mRNA giant behind the Pfizer-partnered COVID vaccine and a broad oncology pipeline. Its use of Acuitas LNPs and scale of LNP manufacturing makes it the dominant incumbent reference point for Luca's target market.
• Moderna: Moderna is the largest fully integrated mRNA/LNP company, with proprietary lipid delivery technology and an approved vaccine franchise. It anchors the competitive ceiling in any LNP-enabled therapeutic market Luca targets.
• CureVac: CureVac is a larger mRNA therapeutics company with proprietary LNP formulations. It operates more broadly across infectious disease, oncology, and protein-replacement therapy compared to Luca's narrower platform focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Luca AICell